RVMD · Revolution Medicines Inc
Price
Snapshot
50 fields · last close| Market Cap | $38.14B |
| P/E | — |
| Float | 206.9M |
| Beta | 1.44 |
| Volatility | 36.0% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 70.1 |
| Price | 182.67 |
| Change | +2.65% |
| Prev Close | 177.96 |
| Open | 188.86 |
| Day Low | 175.91 |
| Day High | 189.68 |
| Avg Vol | 2 |
| Avg $ Vol | $408.0M |
| 52W High | 224.31 |
| 52W Low | 49.05 |
| 52W Pos | 76.2% |
| From High | −18.56% |
| From Low | +272.42% |
| Max DD 1Y | −24.95% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −7.15% |
| SMA 50 | −10.07% |
| SMA 200 | +20.48% |
| RSI (14) | 33.5 |
| Vol 30D | 40.0% |
| Vol 90D | 40.5% |
| 1Y Range | 49–224 |
| Daily bars | 536 |
| Perf Week | −6.22% |
| Perf Month | −9.64% |
| Perf Quarter | −1.35% |
| Perf Half Y | +19.73% |
| Perf Year | +259.08% |
| Perf YTD | +131.17% |
| Prev Day | +2.65% |
| Clavix | B- |
| Debt / Eq | 0.16 |
| Curr Ratio | 7.14 |
| Int Cover | — |
| FCF Margin | — |
| Rev Growth | — |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 20 / 35 |
Clavix risk grade
regraded every trading dayRVMD grades B-, 70.1 of 100. Steadiest on Sector Resilience (63), most exposed on Macro Resilience (50, mixed). 1 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 20 of 35 in Biotechnology by Clavix score.
How rough the ride is
| RVMD | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.44 | 0.51 |
| Volatilityannualized | 36.0% | 14.6% |
| Max drawdown, past yearworst peak-to-trough fall | −25.0% | — |
| Typical daily movemedian absolute daily change | 1.34% | — |
| Days beyond ±3%of the last 252 sessions | 53 (21%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| RVMD | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.44 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| RVMD | |
|---|---|
| 1 week | −6.2% |
| 1 month | −9.6% |
| Year to date | +131.2% |
| 1 year | +259.1% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| RVMD | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 4 Sep |
| Average score0 most bearish, 100 most bullish | 70 |
| Bullish · bearisharticles above 60 · below 40 | 25 · 3 |
| Directionarticles whose tone is improving vs worsening | 25 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| RVMD | |
|---|---|
| Revenue growthyear over year | — |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openRevolution Medicines reported that the European Medicines Agency's drug review committee (CHMP) issued a positive opinion recommending RASONQUE for approval as a standalone treatment for adults with pancreatic cancer that has spread and who have already been treated. The recommendation is based on the Phase 3 RASolute 302 trial, which compared RASONQUE to standard chemotherapy.
William Blair began covering Revolution Medicines with an Outperform rating and a $226 price target, noting the stock has already climbed 124% year-to-date and pointing to growth opportunities beyond the company's pancreatic cancer work.
A European Medicines Agency committee recommended EU approval of Revolution Medicines' drug Rasonque for adults with pancreatic cancer that has spread and worsened after at least one prior treatment.
International Biotechnology Trust (IBT) portfolio manager Marek Poszepczynski discussed emerging cancer treatments at a Boston conference and highlighted the trust's fifth straight year of beating its benchmark index. He mentioned Revolution Medicines' pancreatic cancer treatment prospects, AstraZeneca's AVANZAR trial, Summit Therapeutics' data that could challenge Merck's KEYTRUDA, and Moderna's melanoma results. He attributed IBT's outperformance to disciplined selling at target valuations, managing clinical trial risk, and acquisition activity that absorbed over a quarter of the portfolio in the past year.
Revolution Medicines announced that the EMA's CHMP issued a positive opinion recommending marketing authorization in the EU for RASONQUE (daraxonrasib), an oral once-daily therapy, for adult patients with metastatic pancreatic cancer who have had at least one prior treatment. The recommendation follows an expedited review and was supported by a Phase 3 trial showing patients on the drug had a 60% lower risk of death than those on chemotherapy.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| BIIB | Biogen Inc | B+ | $34.37B | 41.19 | 0.10 | Compare |
| ALNY | Alnylam Pharmaceuticals Inc | C+ | $31.02B | 38.39 | 0.37 | Compare |
| NTRA | Natera Inc | B- | $56.71B | — | 1.54 | Compare |
| INCY | Incyte Corp | B+ | $22.92B | 14.21 | 0.79 | Compare |
| UTHR | United Therapeutics Corp | B | $22.87B | 17.44 | 0.50 | Compare |
| INSM | Insmed Inc | C | $21.02B | — | 0.83 | Compare |
| REGN | Regeneron Pharmaceuticals Inc | B+ | $81.41B | 18.81 | 0.13 | Compare |
| MRNA | Moderna Inc | F | $87.04B | — | 1.17 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.